These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31464657)

  • 1. Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways.
    Huppertz A; Grond-Ginsbach C; Dumschat C; Foerster KI; Burhenne J; Weiss J; Czock D; Purrucker JC; Rizos T; Haefeli WE
    BMC Pharmacol Toxicol; 2019 Aug; 20(1):53. PubMed ID: 31464657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
    Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
    Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of
    Skripka AI; Krupenin PM; Kozhanova ON; Kudryavtseva AA; Fedina LV; Akmalova KA; Bochkov PO; Sokolova AA; Napalkov DA; Sychev DA
    Drug Metab Pers Ther; 2024 Jun; 39(2):89-97. PubMed ID: 38943286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure.
    Cortese F; Scicchitano P; Gesualdo M; Ricci G; Carbonara S; Franchini C; Pia Schiavone BI; Corbo F; Ciccone MM
    Curr Med Chem; 2017 Nov; 24(34):3813-3827. PubMed ID: 28820069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study.
    Perlman A; Goldstein R; Choshen Cohen L; Hirsh-Raccah B; Hakimian D; Matok I; Kalish Y; Singer DE; Muszkat M
    CNS Drugs; 2021 Mar; 35(3):305-316. PubMed ID: 33595834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.
    Roşian AN; Roşian ŞH; Kiss B; Ştefan MG; Trifa AP; Ober CD; Anchidin O; Buzoianu AD
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32316515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
    Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
    Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Apixaban Prescribing Patterns for Nonvalvular Atrial Fibrillation in Hospitalized Patients.
    Gibson CM; Smith CB; Davis S; Scalese MJ
    Ann Pharmacother; 2018 Jan; 52(1):54-59. PubMed ID: 28799408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
    Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.
    Hijazi Z; Hohnloser SH; Andersson U; Alexander JH; Hanna M; Keltai M; Parkhomenko A; López-Sendón JL; Lopes RD; Siegbahn A; Granger CB; Wallentin L
    JAMA Cardiol; 2016 Jul; 1(4):451-60. PubMed ID: 27438322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.
    Gulilat M; Tang A; Gryn SE; Leong-Sit P; Skanes AC; Alfonsi JE; Dresser GK; Henderson SL; Rose RV; Lizotte DJ; Teft WA; Schwarz UI; Tirona RG; Kim RB
    Can J Cardiol; 2017 Aug; 33(8):1036-1043. PubMed ID: 28754389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
    Yamazaki-Nishioka M; Kogiku M; Noda M; Endo S; Takekawa M; Kishi H; Ota M; Notsu Y; Shimizu M; Yamazaki H
    Xenobiotica; 2019 Sep; 49(9):1001-1006. PubMed ID: 30216091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
    Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
    Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation.
    Nissan R; Spectre G; Hershkovitz A; Green H; Shimony S; Cooper L; Nakav S; Shochat T; Grossman A; Fuchs S
    Drugs Aging; 2019 Feb; 36(2):165-177. PubMed ID: 30460518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
    Byon W; Garonzik S; Boyd RA; Frost CE
    Clin Pharmacokinet; 2019 Oct; 58(10):1265-1279. PubMed ID: 31089975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
    Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.